MAIA reports 17.8-month median OS in NSCLC trial; new partial response after 20 months

MAIA Biotechnology, Inc.

Median overall survival of 17.8 months for 22 third-line NSCLC patients, nearly triple the 5-6 month SOC.
95% CI lower bound of 12.5 months and 99% CI lower bound of 10.8 months shown.
New partial response (>=30% tumor reduction) observed after >20 months on treatment.
Longest-surviving patient reached 24.3 months and completed 32 cycles of therapy.
Potential FDA decision for ateganosine as early as next year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.